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Background aims. Bone marrowederived mesenchymal stromal cells (BMSCs) are a promising therapeutic option for treating
Duchenne muscular dystrophy (DMD). Myogenic differentiation occurs in the skeletal muscle of the mdx mouse (a mouse
model of DMD) after BMSC transplantation. The transcription factor bone morphogenic protein 4 (BMP4) plays a crucial
role in growth regulation, differentiation and survival of many cell types, including BMSCs. We treated BMSCs with BMP4
or the BMP antagonist noggin to examine the effects of BMP signaling on the myogenic potential of BMSCs in mdx mice.
Methods. We added BMP4 or noggin to cultured BMSCs under myogenic differentiation conditions. We then injected
BMP4- or noggin-treated BMSCs into the muscles of mdx mice to determine their myogenic potential. Results. We found
that the expression levels of desmin and myosin heavy chain decreased after treating BMSCs with BMP4, whereas the
expression levels of phosphorylated Smad, a downstream target of BMP4, were higher in these BMSCs than in the controls.
Mdx mouse muscles injected with BMSCs pretreated with BMP4 showed decreased dystrophin expression and increased
phosphorylated Smad levels compared with muscles injected with non-treated BMSCs. The opposite effects were seen after
pretreatment with noggin, as expected. Conclusions. Our results identiﬁed BMP/Smad signaling as an essential negative
regulator of promyogenic BMSC activity; inhibition of this pathway improved the efﬁciency of BMSC myogenic differen-
tiation, which suggests that this pathway might serve as a target to regulate BMSC function for better myogenic differen-
tiation during treatment of DMD and degenerative skeletal muscle diseases.
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Duchenne muscular dystrophy (DMD) is an X-
linked inherited muscular disorder characterized by
the absence of dystrophin [1]. Without dystrophin,
the muscles undergo repetitive degeneration and
regeneration cycles leading to muscle ﬁbrosis and
weakness [2]. Various attempts have been made to
overcome DMD, including steroid treatment [3,4],
gene therapy [5,6] and stem cell therapy [7]. Stem
cellebased therapy provides a promising treatment
option for DMD because healthy stem cells can
restore dystrophin expression in vitro and in vivo.
Many studies have demonstrated that mesenchymal
stromal cells induce dystrophin protein production
in mdx mice [8], dogs [9] and humans [10]. On the*These authors contributed equally to this work.
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cells were obtained in mdx mouse skeletal muscle
after bone marrowederived mesenchymal stromal
cell (BMSC) transplantation [11]. However, because
defective muscle regeneration cannot counteract
repetitive degeneration, the myogenic differentiation
capacity of BMSCs has unique therapeutic potential.
Bone morphogenetic proteins (BMPs) are mem-
bers of the transforming growth factor-b (TGFeb)
superfamily, and they regulate cell commitment and
differentiation through intracellular proteins called
Smads [12,13]. Initially, BMP4 was shown to play
critical roles in osteoblast differentiation [14]. More
recently, it was revealed that BMP4 also modulates
myogenic differentiation in BMSCs. Grajales et al.ﬁliated Hospital, Sun Yat-sen University, Guangzhou 510080, PR China.
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1214 C. Jiqing et al.[15] reported that BMP4 enhanced cardiac
myogenic development and suppressed skeletal
myogenesis, leading to loss of “stemness” in BMSCs.
Another study showed that retinoic acid enhanced
skeletal myogenesis in stem cells by inhibition of
BMP signaling [16]. Noggin, a BMP antagonist, is
crucial for proper differentiation of muscle progeni-
tor cells, and it acts through inhibition of local BMP
signaling during embryonic muscle differentiation
[12,17]. Thus, we hypothesized that inhibition of
BMP/Smad signaling may promote the myogenic
differentiation of BMSCs in vitro and increase
restored dystrophin in muscles of mdx mice.
Therefore, the objective of the present study was to
determine the effects of BMP4 on the myogenic
differentiation potential of BMSCs in vivo and
in vitro and on the molecular mechanism of BMP4
function in this context.Methods
Bone marrow isolation and culture
Bone marrow was obtained from 6- to 8-week-old
C57 mice. Mice were euthanized by means of cer-
vical dislocation, and bone marrow was slowly
ﬂushed out the tibia and femur into lymphocyte
separation medium, in which it was proportionally
diluted with phosphate-buffered saline (PBS). After
density gradient centrifugation, mononuclear cells
were collected and centrifuged for 4 min at 1000g
twice, after dilution in PBS. The cells were then
cultured in low-glucose Dulbecco’s modiﬁed Eagle’s
medium (LG-DMEM, Gibco, Invitrogen) contain-
ing 10% fetal bovine serum (FBS, Gibco, Invitrogen)
and 1% penicillin/streptomycin and were subse-
quently incubated at 37C in 5% CO2. After 3 days,
the medium was changed, and the non-adherent cells
were discarded. The adherent cells were trypsinized
with 0.25% trypsineethylene diamine tetra-acetic
acid (Gibco, Invitrogen) when well-developed col-
onies reached near-conﬂuency, and they were seeded
into fresh plates for further expansion.Characterization of BMSCs
To determine the purity of BMSCs, ﬂow cytometric
analysis of BMSC cell surface marker expression was
performed. Cells that were 80% to 90% conﬂuent
were washed in PBS and centrifuged at 1000g for 4
min after trypsinization. Cells were then re-suspended
in equal volumes of ice-cold PBS and 100% ethanol
and incubated on ice for 30 min. Cells were incubated
in PBS containing CD29, CD34, CD44, CD45 and
CD105 primary antibodies (Cell Signaling Technol-
ogy) for 30 min at 37C. After incubation, cells werewashed with PBS containing 1% bovine serum albu-
min (BSA) 3 times and then were centrifuged at
12,000g for 5 min at 4C between each wash. A
Becton Dickinson FACS Scan was used for
ﬂuorescence-activated cell-sorting (FACS) analysis.
Cells were then tested for the ability to differentiate
into adipogenic and osteogenic lineages through the
use of oil red O staining and alizarin red staining, as
described previously [18].Induction of myogenic differentiation
BMSCs that reached sub-conﬂuence were treated
with 5-azacytidine (5-Aza, Sigma) for 24 h; cells were
then assigned to three treatments groups, and their
media was changed as follows: group 1 (control),
DMEM supplemented with 2% horse serum (HS,
Gibco, Invitrogen); group 2, DMEM supplemented
with 10 ng/mL recombinant human BMP4 (Invi-
trogen) and 2% HS; group 3, DMEM supplemented
with 100 ng/mL recombinant human noggin (Invi-
trogen) and 2% HS. The culture media was changed
every 2 days. The expression of target proteins was
analyzed after 14 days and 21 days of culture.Animal injection
Twenty-two mdx mice (6e8 weeks old) were divided
into four groups (with four mice in the control
group, and six mice each in the other three treatment
groups): group 1 (control), radiotherapy only; group
2, transplantation with BMSCs pre-treated with
5-Aza; group 3, transplantation with BMSCs pre-
treated with 5-Aza þ BMP4 (3 days); group 4,
transplantation with BMSCs pretreated with
5-Aza þ noggin (3 days). All mice were irradiated
(total body with 6 Gy) from a 60 Co source. Three
days after irradiation, 3  106 BMSCs were infused
through the tail vein per mouse. Muscle tissue was
harvested 12 weeks after injection. The mice were
housed in a speciﬁc pathogen-free animal facility at
the Laboratory Animal Center of Sun-Yet University
(Guang Zhou, China), which was purchased from
The Model Animal Research Center of Nanjing
University (Nanjing, Jiangsu, China). All animal
experiments were performed in accordance with the
Sun-Yet University Guidelines for Animal Care.Immunoﬂuorescent staining
Cells were ﬁxed in 4% paraformaldehyde and
blocked with 5% BSA; they were then incubated with
the following primary antibodies: rabbit polyclonal
anti-desmin (1:200; Abcam), rabbit polyclonal anti-
myosin heavy chain (MHC) (1:50; Santa Cruz) and
rabbit polyclonal anti-Smad or antiephosphor-Smad
Figure 1. Characterization of cultured BMSCs. (A) Oil red O staining (blue arrow) shows the formation of lipid vacuoles, which indicates
adipogenic differentiation of BMSCs. (B) Alizarin red staining (black arrow) shows the formation of calcium deposits, which indicates
osteogenic differentiation of BMSCs. (C) Flow cytometric analysis of BMSCs stained with antibodies against myogenic surface antigens.
Y-axis: number of events; X-axis: ﬂuorescence intensity; red lines: speciﬁc antibodies; blue lines: control antibodies.
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min at room temperature. Cells were then washed 3
times with PBS. Cy3-conjugated goat anti-rabbit sec-
ondary antibody (1:400, Millipore) was used to detect
the localization of anti-desmin and anti-MHC anti-
bodies.Cell nuclei were stainedwith 40-6-diamidino-2-
phenylindole (Sigma). Immunoﬂuorescence analysis
was performed 12 weeks after BMSC transplantation
on transverse, serial cryosections (6 mm in thickness)
after ﬁxation with cold acetone. Slides were incubated
overnight at 4C with an anti-dystrophin rabbit poly-
clonal primary antibody (1:400, Abcam) followed by
1-h incubation with Cy3-conjugated goat anti-rabbit
secondary antibody (1:400, Millipore) in 1% BSA.
The other steps were performed as described above.Western blotting
At predetermined experimental time points, cells were
harvested and lysed in Radio Immunoprecipitation
Assay (RIPA) buffer (Millipore) (10 mmol/L Tris, pH
7.4, 150 mmol/L NaCl, 1 mmol/L ethylene diamine
tetraacetic acid (EDTA), 0.1% sodium dodecyl sulfate
(SDS), 1 mmol/L NaF, 1 mmol/L Na3VO4, 1 mmol/L
phenylmethanesulfonyl ﬂuoride (PMSF), 1 mg/mL
aprotinin and 1 mg/mL leupeptin) after ice-cold PBS
(3). Protein concentration was determined with the
use of a BCA assay kit (bicinchoninic acid; Millipore).
Cell lysates were loaded and separated on a 10%SDSepolyacrylamide gel electrophoresis (PAGE) gel.
Proteins were transferred to polyvinylidene ﬂuoride
membranes (Millipore) that were blocked with 5%
BSA for 1 h. The membranes were probed with rabbit
anti-desmin (1:1000; Abcam), anti-MHC (1:200;
Santa Cruz), anti-phosphorylated Smad (p-Smad)
(1:1000, Cell Signaling Technology), anti-Smad
(1:1000; Cell Signaling Technology) and anti-
eglyceraldehyde-3-phosphate dehydrogenase (1:1000;
Cell Signaling Technology) monoclonal antibodies
at 4C, overnight. The membranes were incubated
with a horseradish-polypeptidaseeconjugated second-
ary antibody (1:1000; Cell Signaling Technology) for
1 h at room temperature. Protein bands were visualized
by means of enhanced chemiluminescence, and band
intensity was quantiﬁedwith the use of ImageJ software
(National Institutes of Health). Tissue samples from
the gastrocnemius muscle were homogenized in a lysis
buffer containing 10% SDS, 70mmol/L Tris-HCl, pH
6.8, 5% b-mercaptoethanol and 10 mmol/L ethylene
diamine tetra-acetic acid supplemented with a cocktail
of protease and phosphatase inhibitors (Sigma). Nuclei
and cellular debris were discarded by centrifuging
at 10,000g for 10 min at 4C. Homogenates were
separated by use of 6% SDS-PAGE. The membranes
were probed using the following antibodies: anti-
dystrophin, anti-Smad and antiep-Smad (described
above). The remaining steps were carried out as
described above.
Figure 2. Expression of desmin/MHC and Smad/p-Smad in BMSCs exposed to BMP4/noggin after induction with 5-Aza. Immunoﬂuo-
rescent staining and Western blot analysis of desmin and MHC expression indicated baseline expression in BMSCs after induction with
5-Aza and 2% HS for 13 days and 20 days, respectively. On exposure to BMP4, expression of desmin and MHC was decreased, and, on
exposure to noggin, expression was enhanced. Immunoﬂuorescent staining and Western blot analysis of Smad and p-Smad showed that
p-Smad levels were clearly upregulated after BMSC exposure to BMP4 and clearly downregulated after BMSC exposure to noggin after
induction with 5-Aza. Levels of Smad showed no signiﬁcant difference after exposure to BMP4 or noggin when compared with controls.
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Characterization of mouse BMSCs
BMSCs were deﬁned by cell surface antigen
expression and in vitro differentiation potential. We
found that BMSCs in our study were able to adopt
adipogenic (Figure 1A) and osteogenic (Figure 1B)
phenotypes. Flow cytometric analysis showed that
BMSCs were positive for the MSC markers CD29,
CD44 and CD105 and negative for the hematopoi-
etic markers CD45 and CD34 (Figure 1C).Expression of desmin/MHC and Smad/p-Smad in
BMSCs exposed to BMP4/noggin after induction with
5-Aza
As shown in Figures 2 and 4, expression of desmin
and expression of MHC were detected by immuno-
ﬂuorescent staining and Western blot analysis. Des-
min expression and MHC expression were detected
after 5-Aza treatment. However, after exposure to
BMP4 (10 ng/mL), the expression of desmin and
MHCwere repressed. Conversely, desmin expressionand MHC expression were enhanced after cells were
stimulated with noggin (100 ng/mL). Because BMP4
activates the members of the Smad family, initiating
an intracellular cascade, we further investigated the
effects of BMP4/noggin on the myogenic differentia-
tion of BMSCs after induction with 5-Aza by analysis
of Smad activation. We performed immunoﬂuores-
cent staining and Western blot analysis to examine
protein Smad and p-Smad expression levels. As
shown in Figures 2 and 4, Smad levels determined
after treatment with 5-Aza alone did not change after
exposure to BMP4 or noggin. However, p-Smad
levels were clearly upregulated or downregulated
when BMSCs treated with 5-Aza were exposed to
BMP4 or noggin, respectively.Expression of dystrophin and p-Smad in muscles of mdx
mice injected with BMSCs pre-treated with BMP4/
noggin
To test whether BMP4/noggin treatment changed
the myogenic differentiation potential of BMSCs in
muscles of mdx mice, the expression of dystrophin
Figure 3. Expression of dystrophin and p-Smad in the muscles of mdx mice injected with BMSCs pre-treated with BMP4/noggin after
induction with 5-Aza. Immunoﬂuorescent staining andWestern blot analysis of dystrophin and p-Smad was performed in muscle tissue from
mdx mice injected with BMSCs. Low expression of dystrophin was seen on the cell membrane of mdx mice without BMSC transplantation,
and dystrophin expression was increased in cell membranes after BMSC transplantation. However, expression of dystrophin was clearly
decreased in BMSCs pretreated with BMP4 compared with BMSCs induced with 5-Aza alone. Conversely, dystrophin was clearly increased
in groups of BMSCs pretreated with noggin after 5-Aza induction, compared with groups of BMSCs induced with 5-Aza alone. Expression
of p-Smad was clearly upregulated in BMSCs pretreated with BMP4, and it was clearly downregulated in groups of BMSCs pretreated with
noggin after 5-Aza induction, compared with BMSCs induced with 5-Aza alone.
BMP4 inhibits myogenic differentiation of BMSCs 1217and p-Smad were analyzed. As shown in Figures 3
and 5, in comparison to muscles of mdx mice injec-
ted with BMSCs (controls), dystrophin expression
was clearly decreased inmuscles injected with BMSCs
that had been pretreated with BMP4, whereas levels
were evidently increased in muscles pretreated with
noggin. We also found that p-Smad expression was
clearly increased in muscles of mdxmice injected with
BMP4-treated BMSCs and visibly decreased in mus-
cles of injected with noggin-treated BMSCs.Discussion
In the present study, we cultured BMSCs with 5-Aza,
a compound that promotes DNA hypomethylation,
which, in turn, leads to gene activation. This
compound activates myogenic gene expression in
mesenchymal stromal cells, inducing myogenic dif-
ferentiation. To investigate the effects of BMP4 on the
myogenic differentiation potential of BMSCs, cell
cultures were supplemented with BMP4 or noggin.
The addition of BMP4 to BMSC cultures inhibited
myogenesis in vitro. Conversely, noggin induced a
myocyte phenotype when added to 5-Azaetreated
BMSC cultures, as determined by analysis of
myogenic protein expression. This suggested that
BMP4 has an inhibitory role in the myogenic differ-
entiation of BMSCs after 5-Aza treatment. This was
consistent with previous reports by Grajales et al. [15]
and Kennedy et al. [16], who reported that BMP4
suppressed skeletal myogenic differentiation. The
BMP4 intracellular signaling pathway involves a spe-
ciﬁc set of receptor-mediated Smad proteins, and theinduction of Smads was shown to negatively regulate
myogenic differentiation of C2C12 myoblasts, em-
bryonic stem cells and mesenchymal stromal cells
[12]. We further investigated changes in Smad phos-
phorylation in BMSCs exposed to BMP4/noggin after
induction with 5-Aza. As expected, BMP4 increased
p-Smad expression, whereas exposure to noggin had
the opposite effect. These results demonstrated that
BMP4 inhibited the myogenic differentiation of
BMSCs through the Smad signaling pathway.
Previous studies showed that expression of TGF-
b superfamily members (including BMP4) increased
in the muscles of mdx mice [12,19]. These studies
implicated intracellular Smad signaling as a novel
player in DMD pathology, suggesting that the BMP/
Smad signaling pathway may be directly involved in
regulating myogenic differentiation of transplanted
BMSCs. On the basis of our in vitro results, we
injected BMP4-treated or noggin-treated BMSCs
into the muscles of mdx mice to determine their
myogenic potential. Our results showed that BMSCs
pre-treated with BMP4 reduced dystrophin expres-
sion in the muscles of mdx mice by upregulating the
Smad signaling pathway, whereas BMSCs pre-
treated with noggin showed increased dystrophin
expression in the muscles of mdx mice. This may
have been caused by downregulation of the Smad
signaling pathway before transplantation.
It is well known that the main obstacle preventing
the application of BMSC transplantation in the
treatment of muscle disorders is ineffective myogenic
differentiation in vivo. For example, Gussoni et al.
[10] reported that on analysis of muscle biopsies from
Figure 4. Quantitative analysis of expression of desmin, MHC,
p-smad, and smad in BMSCs exposed to BMP4/noggin detected
by Western blot.
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plantation, the presence of donor nuclei was only
0.5% to 0.9%. Nair et al. [20] did not detect dys-
trophin in a 9-year-old boy with Diamond-Blackfan
anemia and Duchenne muscular dystrophy who
underwent successful allogeneic hematopoietic stem
cell transplantation. Our results showed that sup-
pression of BMP/Smad signaling promoted the
myogenic differentiation of BMSCs and restored
dystrophin expression in the muscle tissue of mdx
mice. This suggests that the inhibition of BMP/Smad
signaling in BMSCs undergoing myogenic differen-
tiation before transplantation can efﬁciently increase
the number of myogenic cells and the expression of
dystrophin in skeletal muscles of mdx mice. How-
ever, myogenic differentiation of BMSCs varies with
the concentration of BMP4 and is affected by several
unknown factors. Thus, further studies are required
to investigate the effect of the BMP/Smad signaling
on the myogenic differentiation potential of BMSCs.
This may be achieved by transfecting the cells with a
lentivirus containing BMP4 and assessing the effects
on skeletal muscle in mdx mice.
In summary, our results indicate that BMP/
Smad signaling is an essential negative regulator ofFigure 5. Quantitative analysis of expression of dystrophin and
p-smad in muscles of mdx mice injected with BMSCs pre-treated
with BMP4/noggin detected by Western blot.myogenic differentiation in BMSCs. The identiﬁca-
tion of BMP/Smad signaling as an essential negative
regulator of promyogenic BMSC activity suggests
that this pathway might serve as a pharmacological
target to regulate BMSC function during treatment of
DMDand other degenerative skeletal muscle diseases
and might improve the efﬁciency of BMSC therapy.Acknowledgments
This study was supported by a grant from the Na-
tional Natural Science Fund of China (30370510,
30870851 and 81271401), the Technology Plan
Project of Guangdong Province (2011A030400006)
and the joint fund of National Nature Science
Foundation of China and Natural Science Founda-
tion of Guangdong Province (U1032004).Disclosure of interests: The authors have no
commercial, proprietary, or ﬁnancial interest in the
products or companies described in this article.References
[1] Hoffman EP, Knudson CM, Campbell KP, Kunkel LM.
Subcellular fractionation of dystrophin to the triads of skel-
etal muscle. Nature 1987;330:754e8.
[2] Lee EJ, Kim AY, Lee EM, Lee MM, Min CW, Kang KK,
et al. Therapeutic effects of exon skipping and losartan on
skeletal muscle of mdx mice. Pathol Int 2014;64:388e96.
[3] Baltgalvis KA, Call JA, Nikas JB, Lowe DA. Effects of
prednisolone on skeletal muscle contractility in mdx mice.
Muscle Nerve 2009;40:443e54.
[4] Keeling RM, Golumbek PT, Streif EM, Connolly AM.
Weekly oral prednisolone improves survival and strength in
male mdx mice. Muscle Nerve 2007;35:43e8.
[5] Bostick B, Yue Y, Lai Y, Long C, Li D, Duan D. Adeno-
associated virus serotype-9 microdystrophin gene therapy
ameliorates electrocardiographic abnormalities in mdx mice.
Hum Gene Ther 2008;19:851e6.
[6] Wang B, Li J, Fu FH, Xiao X. Systemic human mini-
dystrophin gene transfer improves functions and life span of
dystrophin and dystrophin/utrophin-deﬁcient mice. J Orthop
Res 2009;27:421e6.
[7] Meregalli M, Farini A, Parolini D, Maciotta S, Torrente Y.
Stem cell therapies to treat muscular dystrophy: Progress to
date. BioDrugs 2010;24:237e47.
[8] Walsh S, Nygren J, Ponten A, Jovinge S. Myogenic reprog-
ramming of bone marrow derived cells in a W41Dmd(mdx)
deﬁcient mouse model. PLoS One 2011;6:e27500.
[9] Nitahara-Kasahara Y, Hayashita-Kinoh H, Ohshima-
Hosoyama S, Okada H, Wada-Maeda M, Nakamura A, et al.
Long-term engraftment of multipotent mesenchymal stromal
cells that differentiate to form myogenic cells in dogs with
Duchenne muscular dystrophy. Mol Ther 2012;20:168e77.
[10] Gussoni E, Bennett RR, Muskiewicz KR, Meyerrose T,
Nolta JA, Gilgoff I, et al. Long-term persistence of donor
nuclei in a Duchenne muscular dystrophy patient receiving
bone marrow transplantation. J Clin Invest 2002;110:807e14.
[11] Feng SW, Chen F, Cao J, Yu MJ, Liang YY, Song XM, et al.
Restoration of muscle ﬁbers and satellite cells after isogenic
BMP4 inhibits myogenic differentiation of BMSCs 1219MSC transplantation with microdystrophin gene delivery.
Biochem Biophys Res Commun 2012;419:1e6.
[12] Shi S, Hoogaars WM, de Gorter DJ, van Heiningen SH,
Lin HY, Hong CC, et al. BMP antagonists enhance myogenic
differentiation and ameliorate the dystrophic phenotype in a
DMD mouse model. Neurobiol Dis 2011;41:353e60.
[13] Markowski DN, Helmke BM, Meyer F, von Ahsen I,
Nimzyk R, Nolte I, et al. BMP4 increases expression of
HMGA2 in mesenchymal stem cells. Cytokine 2011;56:
811e6.
[14] Okamoto M, Murai J, Yoshikawa H, Tsumaki N. Bone
morphogenetic proteins in bone stimulate osteoclasts and
osteoblasts during bone development. J Bone Miner Res
2006;21:1022e33.
[15] Grajales L, Garcia J, Geenen DL. Induction of cardiac
myogenic lineage development differs between mesenchymal
and satellite cells and is accelerated by bone morphogenetic
protein-4. J Mol Cell Cardiol 2012;53:382e91.
[16] Kennedy KA, Porter T, Mehta V, Ryan SD, Price F,
Peshdary V, et al. Retinoic acid enhances skeletal muscleprogenitor formation and bypasses inhibition by bone
morphogenetic protein 4 but not dominant negative beta-
catenin. BMC Biol 2009;7:67.
[17] Linker C, Lesbros C, Stark MR, Marcelle C. Intrinsic signals
regulate the initial steps of myogenesis in vertebrates.
Development 2003;130:4797e807.
[18] Feng SW, Lu XL, Liu ZS, Zhang YN, Liu TY, Li JL, et al.
Dynamic distribution of bone marrow-derived mesenchymal
stromal cells and change of pathology after infusing into mdx
mice. Cytotherapy 2008;10:254e64.
[19] Sterrenburg E, van der Wees CG, White SJ, Turk R, de
Menezes RX, van Ommen GJ, et al. Gene expression
proﬁling highlights defective myogenesis in DMD patients
and a possible role for bone morphogenetic protein 4. Neu-
robiol Dis 2006;23:228e36.
[20] Nair V, Das S, Sharma A, Sharma S, Kaur J, Mishra D.
Successful bone marrow transplantation in a patient with
Diamond-Blackfan anemia with co-existing Duchenne
muscular dystrophy: a case report. J Med Case Rep 2011;
110:216.
